Clinical trials: Inflammatory Myelopathies
Flaccid Hemiplegia, Flaccid Paraplegia
European Paediatric AFM Associated With EV-D68 Follow-up Study.
The study is a follow-up study on children with acute flaccid paresis associated with enterovirus D68 infection. Only children living in Europe are eligible.
- Conditions
- Flaccid Hemiplegia, Flaccid Paraplegia, Flaccid Tetraplegia, Unspecified, Enterovirus D68
- Trial name
- NCT03499366
- Testing
- HFMS, MRC, ACTIVLIM, PedsQl-4.0
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Neuromyelitis Optica Spectrum Disorders
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.
- Trial name
- NCT06068829
- Testing
- Inebilizumab, Rituximab(RTX)
- Volunteers
- 80 people
- Sponsor
- Feng Jinzhou
Diphtheria, Tetanus
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
PRIMARY OBJECTIVES To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3 To…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT01546909
- Testing
- Diphtheria, tetanus, polio and pertussis vaccination
- Where
- 45 sites in France
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy, Neuromuscular Disease
Electromyography to Diagnose Neuromuscular Disorders
This study will investigate problems with muscle weakness and control using electromyography-a test of nerve-muscle cell communication.
- Conditions
- Healthy, Neuromuscular Disease, Postpoliomyelitis Syndrome
- Trial name
- NCT00004553
- Testing
- Electromyography
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Polio, Hepatitis A
Phase IV Study of Concomitant Administration of the sIPV and HepA
This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and HepA-L or HepA-I in children aged 18 months.
- Trial name
- NCT06460545
- Testing
- sIPV (booster dose at 18 months of age), HepA-L, HepA-I
- Where
- 3 sites in China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Diphtheria, Tetanus
Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda
Faced with high rates of immunization drop-out, Uganda's immunization program requires innovative approaches to address this weakness.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT04177485
- Testing
- SMS text reminders
- Volunteers
- 1,962 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Meningococcal Meningitis, Tetanus
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine.
- Conditions
- Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis
- Trial name
- NCT00355121
- Testing
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 26 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis, Myasthenia Gravis
Serum Auto-Antibodies in Neurological Diseases
Under normal conditions our immune system protects us against infections and tumors. The immune system does this by recognizing that the infecting organism or the tumor is foreign to the body and attacking it.
- Conditions
- Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
- Trial name
- SAA (NCT00704626)
- Testing
- Blood Draw, Cheek swab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Davis
Neuromyelitis Optica Spectrum Disorder
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria.
- Trial name
- NCT01845584
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
NMO Spectrum Disorder
ACT with NMOSD Patients and Caregivers Pilot Study
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their…
- Trial name
- NCT05840055
- Testing
- Acceptance and Commitment Therapy
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Poliomyelitis
Effect of Lactoferrin on Polio Seroconversion
A massive decline in cases of poliomyelitis was observed worldwide since 1988; however its transmission continues in Pakistan and Afghanistan.
- Trial name
- NCT04432935
- Testing
- Bovine Lactoferrin
- Where
- Pakistan
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)
This is a study to assess the safety, tolerability, and immunogenicity of V419 (PR5I) when administered as an infant series at 2, 4, and 6 months of age followed by a toddler dose of DAPTACEL™, Prevnar 13™ and PedvaxHIB™ at 15…
- Trial name
- NCT01337167
- Testing
- V419, DAPTACEL™, PedvaxHIB™
- Volunteers
- 1,473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neuromyelitis Optica Spectrum Disorder
A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely disabling disease.
- Trial name
- NCT05284175
- Testing
- Orelabrutinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Peking Union Medical College Hospital
Poliomyelitis
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
The study will assess and compare the immune response to full-dose inactivated polio vaccines (IPV) via intramuscular (IM) administration and of the fractional dose of inactivated poliovirus vaccine (f-IPV) via intradermal (ID)…
- Trial name
- NCT03239496
- Testing
- IPV, f-IPV
- Where
- 4 sites in Dominican Republic, Panama
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
- Trial name
- NCT05346354
- Testing
- Ravulizumab
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Multiple Sclerosis, NMO Spectrum Disorder
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, COVID-19
- Trial name
- COVISEP (NCT04355611)
- Testing
- Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)
- Where
- France
- Volunteers
- 2,465 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics